NGM120

Phase 2Biologic

NNGM Biopharmaceuticals, Inc

NGM120 is one of 65 biologic programs targeting Colorectal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Colorectal CancerPhase 2

Active, not recruiting

Pancreatic CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

Byetta

1 3

MS Contin

Merck & Co.

Preclinical

1 4

NGM120

NNGM Biopharmaceuticals, Inc

Phase 2

1 5

Thiazolidinediones

Sanofi

Preclinical

1 6

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

1 7

Meglitinides

Sanofi

Preclinical

1 8

Chemotherapy Agents

Takeda

Preclinical

1 9

Secretin-Ferring

Ferring

Preclinical

1 10

Concurrent Lenvatinib

TTrans Tasman Radiation Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Colorectal Cancer

NCT07033026

Clinical

Trials by Indication[1]

Adult Subject1 trial

Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects

Completed·NNGM Biopharmaceuticals, Inc·Phase 1·NCT03392116·92 enrolled

Pancreatic Cancer1 trial

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

Completed·NNGM Biopharmaceuticals, Inc·Phase 1/2·NCT04068896·89 enrolled

Colorectal Cancer1 trial

An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

Recruiting·NNGM Biopharmaceuticals, Inc·Phase 2·NCT07033026·136 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for NGM120. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NGM120 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NGM120. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NGM Biopharmaceuticals, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: NNGM Biopharmaceuticals, Inc

NGM120

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Adult Subject1 trial

Pancreatic Cancer1 trial

Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News